Phase IIIa trials represent the final stage in determining whether a drug or medical device can make it to market. These trials normally operate at a larger scale than Phase I or Phase II clinical trials. Because of their larger scale, Phase IIIa trials can have a more difficult time reaching the target number of applicable participants and retaining them until the end of the trial. However, according to recently collected data, the patient retention rate for surveyed company teams has improved on average. Todd Middleton of Cutting Edge Info takes a closer look at the overall increase in patient retention rate and the potential forces driving that increase.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/Causes-of-improved-patient-retention….pdf” width=”100%” height=”900px” style=”border:0;”]